Finland: Recommended vaccinations
Back to search
Export to spreadsheet
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 		 Vaccination not funded by the National Health system
 		 Mandatory vaccination
BirthWeeksMonthsYears
62356121823234610121314-151718
Coronavirus disease (COVID-19)
COVID-19
COVID-193
tuberculosis
BCG4
rotavirus infection
ROTA
ROTA
ROTA
diphtheria
D
D
D
D
d
tetanus
TT
TT
TT
TT
TT
pertussis
acP
acP
acP
acP
acp
acp5
poliomyelitis
IPV
IPV
IPV
IPV
Haemophilus influenzae type b infection
Hib
Hib
Hib
hepatitis B
HepB6
pneumococcal disease1
PCV13
PCV13
PCV13
PCV137
meningococcal disease
MCV4/MenB8
MCV4/MenB9
measles
MEAS10
MEAS
mumps
MUMPS10
MUMPS
rubella
RUBE10
RUBE
varicella2
VAR11
VAR11
human papillomavirus infection
HPV2 (F/M)12
HPV2 (F/M)13
influenza
IIV3/LAIV14
IIV3
hepatitis A
HepA15
tick-borne encephalitis
TBE16

Version:


Footnotes:

  1. The vaccine used is about to change to PCV13 in January 2026. For more information on pneumococcal vaccination and target groups refer to https://thl.fi
  2. Varicella vaccination implemented from 1 September 2017. Catch-up to all those born on 1st January 2006 or after and with no history of varicella.
  3. More information: https://www.julkari.fi/items/84af049c-11d9-46c1-8034-9e75b8030b2f
  4. For specific at risk-groups only (to be given at the earliest age) Vaccine can be given up til 7 years of age.
  5. dtap-vaccine for pregnant women during every pregnancy. dtap-vaccine is also given every 5 year to health and welfare workers who are working with infants.
  6. Risk-groups only.
  7. For more information on pneumococcal vaccination and target groups refer to https://thl.fi
  8. The meningococcal ACWY vaccine and the meningococcal B vaccine are provided free of charge as part of the national vaccination programme to persons who are at increased risk of severe meningococcal infection because of an underlying medical condition or medication: complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. MCV4: the vaccine (Nimenrix) can be given from 6 weeks of age. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, including booster dose timing, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-acwy-rokote#kenelle-meningokokki-acwy-rokote-annetaan MenB: The vaccine (Bexsero) can be given from 2 months of age. The vaccine is given to infants under 6 months of age as a basic series of two or three doses. For children aged six months or older, the basic series includes two doses. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, including booster dose timing, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-b-rokote#jos-tilaat-bexsero-rokotetta-huomioi-tama
  9. MCV4: The meningococcal ACWY vaccine is provided free of charge as part of the national vaccination programme to persons who are at increased risk of severe meningococcal infection because of an underlying medical condition or medication:complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. The vaccine (Menveo) for persons aged 2 years and older: a single dose is given for primary vaccination. If a person aged 2 years and older has previously received one dose of Nimenrix, the vaccination series is completed with one dose of Menveo. Data on the effectiveness of Menveo are limited in adults aged 56–65 years and are lacking in those aged 65 years and older; however, the vaccine may also be administered to persons aged 55 years and older. For detailed guidance, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-acwy-rokote#kenelle-meningokokki-acwy-rokote-annetaan MenB: The meningococcal B vaccine is available free of charge as part of the national vaccination programme to people who are at increased risk of developing a serious meningococcal infection due to their illness or medication: complement deficiency, treatment with complement-inhibiting medication, asplenia, hyposplenia (reduced spleen function), including sickle cell disease, chronic graft-versus-host disease (GvHD) after stem-cell transplantation. The vaccine (Bexsero) for individuals aged 2 years and older: 2 doses, at least one month apart. There is no information on the effectiveness of the vaccine in people over 50 years of age. However, the vaccine can also be given to people over the age of 50. For detailed guidance, please refer to the official information available at: https://thl.fi/ohjeita-ammattilaisille/meningokokki-b-rokote#jos-tilaat-bexsero-rokotetta-huomioi-tama
  10. Recommendation for the first dose to be given at 12 months of age
  11. Further information available at https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/rokotteet-a-o/vesirokkorokote
  12. More information available at https://thl.fi
  13. 2 doses under 15 years old and 3 doses from 15 years and older.
  14. More information: https://thl.fi
  15. For risk-groups only.
  16. TBE vaccination for specific areas in Finland.


More information available at:
https://thl.fi/aiheet/infektiotaudit-ja-rokotukset


--------------------------------------------------------------------------------

MAJOR HISTORICAL CHANGES
1960: Mumps vaccinations for military recruits.
1975: Measles vaccination for 1 year old children.
1975: Rubella vaccination for 11-13 years old girls and seronegative mothers.
1982: Two doses of MMR vaccination at 14-18 months and 6 years of age were introduced in the national childhood vaccination programme.
2009: Rotavirus vaccine introduced at 2, 3 and 5 months to all children (September 2009)
2010: PCV introduced at 3, 5 and 12 months of age to all children (September 2010).
2013: HPV vaccination introduced
2017: Varicella vaccination introduced (1 Sept. 2017) at 18 months, 6 years + catch-up of all born from 1 jan 2006 or after with no history of varicella
2020-21: In school years 2020–2021 and 2021–2022, the vaccine will also be offered to boys in grades 7 to 9 (catch-up vaccinations). The oldest vaccine recipients are those born in 2005.

see https://www.thl.fi/fi/web/rokottaminen/kansallinen-rokotusohjelma/rokotusohjelman-historia

--------------------------------------------------------------------------------

Date of last update: 15 Jan. 2024

--------------------------------------------------------------------------------